Study supports FDG-PET for assessing MCI

04/8/2013 | InternalMedicineNews.com (free registration)

A study comparing two sets of criteria for determining short- to mid-term incident Alzheimer's dementia among people with mild cognitive impairment found that FDG-PET presented as the strongest single positive predictive biomarker for short-term incident cases. The criteria studied were those published by an International Working Group in 2007 and by the National Institute on Aging and the Alzheimer's Association in 2011. The review involved an analysis of 73 patients from multiple centers.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA